ABSORB III Randomized Controlled Trial (RCT)
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2008 participants.
Also called NCT01751906
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 2,008 participants
- Sponsor
- Registry
-
NCT01751906
-
- Other papers using this trial's data
- 3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial
- Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia
- Registry status
- Completed
Technical summary
Registry record NCT01751906. Randomized; single masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2016-09 (actual). Results posted on 2018-02-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ABSORB III Randomized Controlled Trial (RCT)
- Acronym
- ABSORB-III
- Condition
- Coronary Artery Disease
- Condition
- Coronary Artery Stenosis
- Condition
- Coronary Disease
- Condition
- Coronary Stenosis
- Intervention (Device)
- Absorb BVS
- Intervention (Device)
- XIENCE
- Lead sponsor
- Abbott Medical Devices
Record details
- Record id
cardio:ct-nct01751906- Content hash
76b7850b580a3456c040e73e87bfb0e4fc02392e9599898698a03e06e7a7f821